Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs... see more

TSX:TH - Post Discussion

Theratechnologies Inc > NBF report is out
View:
Post by SPCEO1 on Apr 14, 2021 1:44pm

NBF report is out

I am not sure you could really call it a report, however. Not much effort was expended in producing it - I am guessing he may have dedicated 30 minutes to this. It is more evidence of bad blood between the company and Bay Street. The analyst, however, did not reduce his target price, however. Which I was surprised about given the revenue shortfall.

Like all of us, the NBF analyst is perturbed by the jumpy quarterly sales trends. I think that can partly be blamed on attempts to manage quarterly sales, as noted earlier, by stuffing the distribution channel in one quarter and hoping sales pick up enough in the following quarter to cover your tracks. But that pick-up never happens and sales look lumpier than they probably actually are on the ground.
Comment by Wino115 on Apr 14, 2021 2:15pm
If NBF didn't at least review oncology and how the trial just started and what the significant data story told, then it's criminal and clearly a blow-off of the mangement and name. If I recall, his target is well below the current price so if he didn't change it, he is on a sell and believes you will lose money over the next 12-18 months.  This explains two things -- why we keep ...more  
Comment by Wino115 on Apr 14, 2021 2:30pm
BTW, on of THE KEY issues here is that they are not being covered by biotech analysts or oncology analysts.  At this point it's only two middling "healthcare" guys which really doesn't amount to much for Canadian analysts and one NASH only analyst.  The really need to lean on the Soleus guys (& whomever else bought in to that OO) to ask them to introduce them around ...more  
Comment by qwerty22 on Apr 14, 2021 2:38pm
People looking at the transcript, what was the comment Paul made at the end of the call about investor engagement and bringing on new investors (I assumed he was talking about Soleus there)?  
Comment by scarlet1967 on Apr 14, 2021 3:30pm
"People looking at the transcript" What else should we look at to get some insights, any suggestions?
Comment by palinc2000 on Apr 14, 2021 3:45pm
On the capital market side, the recent offering we closed in January has afforded us the resources to further support our strategy to enhance our commercial initiatives, R&D development and working capital needs. Additionally, we are devoting more resources to enhance our outreached to the investment community and the deal has allowed us to cultivate new institutional investors who are focused ...more  
Comment by palinc2000 on Apr 14, 2021 3:49pm
  I am absolutely confident that Theratechnologies now has the resources, talent, and infrastructure needed to succeed, and we're committed to doing so to drive future sustainable growth and value creation for all our stakeholders.
Comment by scarlet1967 on Apr 14, 2021 2:45pm
Does anyone think it's not only professionally unethical but also morally disrespectful for an analyst not to attend the call after getting a handsome commission? What does it take for the company to react? Apart from being humiliated by their analysts add to the list unfair valuation, frustrated loyal investors, bad reputation etc. Do the company's board members care at all or are they ...more  
Comment by scarlet1967 on Apr 14, 2021 3:19pm
I saw a post elsewhere from a longtime investor who happens to be Spceo's client who has lost money on his THTX investment also is about to loose his job with three kids. I have made my voice heard by the company looking forward to seeing others do the same if they think there is a reason!!
Comment by Lee430 on Apr 15, 2021 11:59am
Wino, If I recall correctly these are the two I did not vote for last year and when looking at the vote tabulation I was not alone in that effort....Hopefully some of the highly experienced members of this board will help pull us together as one LARGE voice for some common sense change.  ”Common sense is not so common”
Comment by Wino115 on Apr 15, 2021 1:01pm
That's my plan. Their Board is overloaded with the Montreal Business community stalworts. That is not what a company Board hoping to be a global pharma firm shoudl look like. That's one where they're all looking to cover each others backs with groupthink, get help into the next country club or elite kids school or have solid cocktail banter for the next party. Since they all only know ...more  
Comment by realitycheck4u on Apr 15, 2021 1:11pm
This post has been removed in accordance with Community Policy
Comment by Bucknelly21 on Apr 15, 2021 1:35pm
Thera never disappoints do they, im almost fed up with them... on my last leg 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities